Every 10-Q that Crescent Biopharma, Inc. (CBIO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CBIO filings page.
Crescent Biopharma, Inc., a clinical-stage oncology company, reported a net loss of $24.8 million for Q2 2026 and $48.1 million for the first half of 2026. License revenue totaled $1.0 million year-to-date from its CR-001 collaboration with Kelun, with no revenue in the second quarter.
Operating expenses increased as the pipeline advanced: research and development was $19.4 million in Q2 and $37.3 million year-to-date, while general and administrative costs were $8.7 million in Q2 and $16.6 million year-to-date. Interest expense from prior convertible notes was eliminated after their 2025 conversion, and Crescent booked $1.8 million of other income from a gain on sale of assets.
Cash and cash equivalents were $171.6 million as of June 30, 2026, down from $213.2 million at year-end, after $28.4 million of operating cash outflows and $6.4 million used in investing, including an $80.0 million SKB105 (CR-003) license from Kelun. Total liabilities were modest at $19.5 million against $163.3 million of shareholders’ equity. Management expects existing cash, together with an underwritten offering completed in July 2026, to fund operations for at least twelve months from issuance.
Crescent Biopharma, Inc. filed Amendment No. 1 to its quarterly report for the period ended March 31, 2026 to add previously omitted disclosure about Rule 10b5-1 trading arrangements. The amendment does not change any financial statements or other disclosures from the original filing.
The company reports that on February 25, 2026 seven senior executives adopted pre-arranged “sell-to-cover” Rule 10b5-1 instructions to sell ordinary shares only as needed to cover tax withholding on vesting of restricted stock units and performance stock units granted under company equity plans. As of April 24, 2026, 27,571,935 ordinary shares were outstanding.
Crescent Biopharma, Inc. reported a net loss of $23.3 million for the three months ended March 31, 2026, wider than $15.1 million a year earlier, as it ramps up oncology development. The loss was driven by higher research and development expense of $17.9 million and general and administrative expense of $7.9 million, partly offset by $1.0 million of license agreement revenue from its CR-001 collaboration with Kelun.
Cash and cash equivalents were $189.2 million as of March 31, 2026, with total assets of $199.1 million and shareholders’ equity of $183.8 million. Operating activities used $8.9 million of cash in the quarter, and the company expects existing cash to fund operations for at least twelve months from the financial statement issuance date.
Crescent Biopharma (CBIO) filed its quarterly report for the period ended September 30, 2025. The company reported a net loss of $24.6 million for the quarter and $61.5 million year‑to‑date, driven primarily by research and development of preclinical oncology programs.
Cash and cash equivalents were $133.3 million as of September 30, 2025, and management expects this balance to fund operations for at least twelve months from the financial statement issuance date. Operating cash outflow was $44.8 million for the nine months. R&D expense was $20.3 million in Q3 ($43.1 million YTD); G&A was $5.5 million in Q3 ($18.1 million YTD).
During 2025 the company completed a reverse recapitalization with GlycoMimetics, raised capital via a pre‑closing financing, converted $37.5 million of convertible notes into equity, and redomesticated to the Cayman Islands. Shareholders’ equity improved to $116.6 million from a deficit at year‑end 2024. Ordinary shares outstanding were 13,892,516 as of November 3, 2025.